AFC
EW icon

Ares Financial Consulting’s Edwards Lifesciences EW Stock Holding History

Ares Financial Consulting’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8K Buy
263
+16
+6% +$1.34K 0.02% 379
2026
Q1 		$20.1K Hold
247
– – 0.02% 395
2025
Q4 		$21.1K Buy
+247
New +$20.3K 0.02% 249

Other funds holding EW

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Ares Financial Consulting's EW Position: Q2 2026 in Review

Ares Financial Consulting increased its Edwards Lifesciences (EW) stake by 6.5% in Q2 2026, buying an estimated $1.34K and bringing the position to 263 shares worth $23.8K. The position accounts for 0.02% of the portfolio, ranked #379.

Ares Financial Consulting first reported a position in EW in Q4 2025 and has held it in 3 quarters since. 719 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Ares Financial Consulting held 263 shares of Edwards Lifesciences worth $23.8K as of Q2 2026.
  • Ares Financial Consulting bought 16 Edwards Lifesciences shares in Q2 2026, an estimated $1.34K.
  • Edwards Lifesciences made up 0.02% of Ares Financial Consulting's portfolio in Q2 2026, its #379 holding.
  • Ares Financial Consulting first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
  • 719 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.